Stockwatch: Biogen's belligerent repetition
This article was originally published in Scrip
Two iconic artists are brought together in unlikely combination at an exhibition that opens in Oxford this week. The patterns of William Morris's curtains and wallpapers have a sublime connection with Andy Warhol's prints of Marilyn Monroe – repetition. The theme of repetition also struck me in the most impactful clinical data release of last week.
You may also be interested in...
Rigel and Biogen both released data last week that prompted over-reactions and sensationalism, respectively from analysts, the print media and even the BBC. When something sounds too good to be true, is probably is.
Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.
The era of follow-on medicinal chemistry has largely been eliminated by more comprehensive patent protection. Nowadays, investors trade on the differences in safety and efficacy for similar molecules.